Your session is about to expire
← Back to Search
MRI Monitoring for Prostate Cancer (NA_00067284 Trial)
N/A
Recruiting
Led By Danny Song, M.D.
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically-confirmed prostate cancer
Plan to undergo external radiation treatment of prostate cancer
Must not have
Patients who have chronic kidney disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether using MRI to monitor tissue response during and after radiotherapy for prostate cancer is feasible, and if so, whether it can provide more information than simple anatomic information.
Who is the study for?
This trial is for men with confirmed prostate cancer who are planning to receive external radiation treatment. It's not suitable for those with a cardiac pacemaker, metal implants, chronic kidney disease, an inability to undergo MRI scans, or allergies to gadolinium-based contrast agents.
What is being tested?
The study is testing the use of advanced MRI techniques like MRS, DWI, and DCE during and after radiotherapy to monitor tissue response in prostate cancer patients. The goal is to see if these MRIs can provide early information on tumor recurrence and normal tissue damage.
What are the potential side effects?
There are generally no side effects associated directly with undergoing MRI imaging itself; however, there may be risks related to lying still for long periods during the scan or reactions in those allergic to contrast agents used.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My prostate cancer diagnosis was confirmed through a tissue examination.
Select...
I am planning to receive external radiation for prostate cancer.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have chronic kidney disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
MRI use to predict treatment response
Secondary study objectives
Evaluating MRI use to predict functional radiation treatment dose distribution
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: MRI imagingExperimental Treatment1 Intervention
Use of MRI imaging in conjunction with standard radiation treatment
Find a Location
Who is running the clinical trial?
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
571 Previous Clinical Trials
33,334 Total Patients Enrolled
57 Trials studying Prostate Cancer
3,408 Patients Enrolled for Prostate Cancer
Danny Song, M.D.Principal InvestigatorThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3 Previous Clinical Trials
56 Total Patients Enrolled
2 Trials studying Prostate Cancer
50 Patients Enrolled for Prostate Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are unable to have an MRI scan.You have a heart pacemaker or other electronic/metal implant in your body.I have chronic kidney disease.You are allergic to a type of contrast agent called gadolinium.My prostate cancer diagnosis was confirmed through a tissue examination.I am planning to receive external radiation for prostate cancer.
Research Study Groups:
This trial has the following groups:- Group 1: MRI imaging
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.